PTC Therapeutics stock: Q3 growth lifts 2026 outlook
Published on 10/30/2026 at 00:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly growth and outlook
- PTC Therapeutics reported third-quarter revenue of USD 357.8 million, led by strong product sales and royalty income.
- Sephience generated USD 182 million in quarterly revenue, while the company acquired the ST-920 Fabry disease gene therapy.
- Management raised its full-year 2026 revenue outlook and expects to reach cash flow breakeven this year.
PTC Therapeutics reported strong third-quarter results on October 29, 2026, with total revenue of USD 357.807 million for the period ended September 30. The company said the performance was led by continued momentum for Sephience and supported by royalty revenue. The results and outlook were disclosed in a PTC Therapeutics press release.
Sephience leads commercial growth
Net product revenue reached USD 275.894 million, compared with USD 130.956 million a year earlier. Sephience, PTC's sepiapterin treatment, contributed USD 182 million in the quarter, according to the company. Royalty revenue increased to USD 81.684 million from USD 70.793 million in the prior-year quarter.
Operating income was USD 25.114 million, but PTC recorded a net loss attributable to common stockholders of USD 51.693 million, or USD 0.62 per diluted share. The result included USD 111 million of acquired in-process research and development expense related to the ST-920 asset purchased from Sangamo Therapeutics, as well as USD 19.263 million in debt-extinguishment losses.
Higher guidance, new pipeline asset
PTC raised its full-year 2026 expected total revenue range to USD 1.29 billion to USD 1.32 billion and its product revenue range to USD 960 million to USD 990 million. Management also said it remains on track to reach cash flow breakeven in 2026. These are company projections and remain subject to commercial, regulatory and financing risks.
The ST-920 acquisition adds a Fabry disease gene therapy to the pipeline. PTC expects to complete a Biologics License Application submission in the fourth quarter of 2026. The company reported USD 2.128 billion in cash, cash equivalents and marketable securities at September 30, while total debt stood at USD 536.268 million.
Quote and investor context
Lang & Schwarz quoted PTC Therapeutics at EUR 57.73 on October 29, 2026, at 22:59 Berlin time. The bid was EUR 57.56 and the ask was EUR 57.90. Investors can find the real-time quote of PTC Therapeutics stock on the snapshot page.
PTC Therapeutics at a glance
- Company: PTC Therapeutics, Inc.
- ISIN: US69366J2006
- Ticker: PTCT
- Home exchange: Nasdaq
- Lang & Schwarz quote: EUR 57.73 on October 29, 2026 at 22:59 Berlin time
- Bid / ask: EUR 57.56 / EUR 57.90
- Third-quarter revenue: USD 357.807 million for the period ended September 30, 2026
- Full-year 2026 total revenue guidance: USD 1.29 billion to USD 1.32 billion
Broader market sentiment remains an important backdrop for US-listed biotechnology companies; see the latest S&P 500 market coverage.
